Abstract
Designing an effective nanoparticle for selective drug transport requires careful consideration of the complex biological barriers encountered in transit to the desired target. Here, we review several of these barriers, and provide possible methods for formulating liposomal nanoparticles to overcome them. The methods include the biotinylation of an antibody, and subsequent conjugation to a PEGylated cationic lipid nanoparticle. Additionally, the incorporation of drug, and other relevant characteristics of the nanoparticle are also discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Senior JH (1987) Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 3(2):123–193
Drummond DC, Meyer O, Hong K et al (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51(4):691–743
Gregoriadis G (1988) Liposomes as drug carriers: recent trends and progress. Wiley, Chichester
Patel HM, Moghimi SM (1998) Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system—the concept of tissue specificity. Adv Drug Deliv Rev 32(1–2):45–60, S0169-409X(97)00131-2 [pii]
Papahadjopoulos D, Allen TM, Gabizon A et al (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 88(24):11460–11464
Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1(1):27–30
Yuan F, Dellian M, Fukumura D et al (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55(17):3752–3756
Seymour LW (1992) Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 9(2):135–187
Huang SK, Mayhew E, Gilani S et al (1992) Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 52(24):6774–6781
Jain RK (1989) Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 81(8):570–576
Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50(3 Suppl):814–819
Lipinski CA, Lombardo F, Dominy BW et al (2012) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 64:4–17
Laouini A, Jaafar-Maalej C, Limayem-Blouza I et al (2012) Preparation, characterization and applications of liposomes: state of the art. J Colloid Sci Biotechnol 1(2):147–168
Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33(9):941–951
Kuesters GM, Campbell RB (2010) Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential. Nanomedicine 5(2):181–192
Rodriguez PL, Harada T, Christian DA et al (2013) Minimal “Self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339(6122):971–975. doi:10.1126/science.1229568
Caffrey M (1993) LIPIDAT a database of thermo data and association information on lipid. CRC Press, Boca Raton
Barnadas-Rodriguez R, Sabés M (2001) Factors involved in the production of liposomes with a high-pressure homogenizer. Int J Pharm 213(1):175–186
de Paula Rigoletto T, Silva CL, Santana MHA et al (2012) Effects of extrusion, lipid concentration and purity on physico-chemical and biological properties of cationic liposomes for gene vaccine applications. J Microencapsul 29(8):759–769
Pupo E, Padrón A, Santana E et al (2005) Preparation of plasmid DNA-containing liposomes using a high-pressure homogenization–extrusion technique. J Control Release 104(2):379–396
Wagner A, Vorauer-Uhl K (2011) Liposome technology for industrial purposes. J Drug Deliv 2011:591325. doi:10.1155/2011/591325
Mayer LD, Tai LC, Bally MB et al (1990) Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta Biomembranes 1025(2):143–151
van Etten EW, ten Kate MT, Stearne LE et al (1995) Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. Antimicrob Agents Chemother 39(9):1954–1958
Kan P, Tsao CW, Wang AJ et al (2011) A liposomal formulation able to incorporate a high content of Paclitaxel and exert promising anticancer effect. J Drug Deliv 2011:629234. doi:10.1155/2011/629234
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Richards, S.M., Campbell, R.B. (2017). Piloting Your Nanovehicle to Overcome Biological Barriers. In: Zeineldin, R. (eds) Cancer Nanotechnology. Methods in Molecular Biology, vol 1530. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6646-2_9
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6646-2_9
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6644-8
Online ISBN: 978-1-4939-6646-2
eBook Packages: Springer Protocols